Results 121 to 130 of about 1,188 (167)

Healthcare effects and evidence robustness of reimbursable digital health applications in Germany: a systematic review. [PDF]

NPJ Digit Med
Sippli K, Deckert S, Schmitt J, Scheibe M.   +3 more
europepmc   +1 more source

PTX-loaded, polysorbate 80-functionalized brain-targeting pullulan nanoparticles for drug delivery. [PDF]

Front Pharmacol
Yuan H, Han L, Deng H, Tan Y, Yang Y, Liu Y, Ying J, Fang M, Wei H, Tao Z.   +9 more
europepmc   +1 more source

Cost-utility analysis of ¹⁷⁷Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany. [PDF]

Eur J Nucl Med Mol Imaging
Brinkmann C, Baum RP, Stargardt T.
europepmc   +1 more source

[Cost aspects and reimbursement requirements of phage therapy]. [PDF]

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
Häckl D, Dillschneider J, Elsner C.
europepmc   +1 more source

From Markup to Value: Global Implications of Iran's Cost-plus Pharmaceutical Pricing for Emerging Markets. [PDF]

J Res Pharm Pract
Hayat H.
europepmc   +1 more source

Stellen Google, Amazon, Facebook & Co. wirklich die marktwirtschaftliche Ordnung zur Disposition? [PDF]

, 2014
Haucap, Justus, Kehder, Christiane
core  

Results of health technology assessments of orphan drugs in Germany-lack of added benefit, evidence gaps, and persisting unmet medical needs. [PDF]

Int J Technol Assess Health Care
Kranz P, McGauran N, Ünal C, Kaiser T.
europepmc   +1 more source

Pharmaindustrie in Deutschland: Positive Entwicklung in 2015

, 2016
Kirchhoff, Jasmina
core